Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "rheumatology"

Lupus B Cell Research Points Toward Targeted Therapies

Susan Bernstein  |  January 19, 2018

SAN DIEGO—B cell signaling goes awry in many patients with systemic lupus erythematosus (SLE), triggering pathogenic autoimmune responses and clinical disease. At the Rheumatology Research Foundation’s 2017 Evelyn V. Hess Memorial Lecture, held on Nov. 5 at the ACR/ARHP Annual Meeting, researcher Ignacio Sanz, MD, discussed B cells’ role in this complex disease. Because lupus…

Case Review: Lupus Patient with Acute Disseminating Encephalomyelitis

Teresa Sosenko, MD, Anca Musetescu, MD, PhD, Neha Gandhi, MD, Scott Friedstrom, MD, & Diana Girnita, MD, PhD  |  January 19, 2018

Systemic lupus erythematosus (SLE) is an autoimmune-mediated rheumatic disease characterized by multisystem involvement that can cause significant morbidity and mortality. Acute disseminated encephalomyelitis (ADEM) is a rare, fulminant, autoimmune-mediated, demyelinating disease involving the white matter of the central nervous system (CNS), and is considered a manifestation of neuropsychiatric lupus. Few reported cases involve SLE and…

Predatory Publishing: Know the Difference Between a Financial Scheme and Scholarly Dissemination

Carina Stanton  |  December 20, 2017

It happens every day. A new email pops up in a researcher’s in-box from a journal with a seemingly familiar name and an invitation to publish a research paper, present at a meeting or, perhaps, serve on an editorial board. Like many of her colleagues, Marian Hannan, DSc, MPH, professor of medicine at Harvard Medical…

Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Catherine Kolonko  |  December 20, 2017

According to a large cohort study of pediatric patients, rituximab use is on the rise in the treatment of children diagnosed with vasculitis. Treatment with cyclophosphamide remains common, but it’s beginning to wane. Dialysis and mechanical ventilation also remain common, the study indicates. The retrospective study of hospitalized children in the U.S. included the largest…

Rheumatology Research Foundation Hosts Student, Resident Experience at ACR/ARHP Annual Meeting

From the College  |  December 20, 2017

On Nov. 5, more than 100 students and residents gathered for the Rheumatology Research Foundation’s Student and Resident Experience at the ACR/ARHP Annual Meeting in San Diego. As part of the Foundation’s work to increase the number of rheumatology professionals in the U.S., the event is designed to increase excitement in the field. Attendees enjoyed…

Rheumatology Coding Corner Answers: 2017 End-of-Year Quiz

From the College  |  December 19, 2017

Take the challenge. 1. B—No. CPT 99358, prolonged evaluation and management service can be billed before or after direct patient care, first hour or 99539 —each additional 30 minutes (list separately in addition to code for prolonged service). This code cannot be used to bill a higher level E/M visit code. According to 2017 CPT:…

Rheumatology Coding Corner Questions: 2017 End-of-Year Quiz

From the College  |  December 19, 2017

1. A 68-year-old new female patient has an appointment to see the rheumatologist in four days. The patient has her medical records sent over from her primary care physician, neurologist and endocrinologist for the rheumatologist to review prior to the visit. Upon receipt, the rheumatologist spends 55 minutes reviewing the records and making notes. Can…

ARHP Master Designation Award Will Debut at the 2018 ACR/ARHP Annual Meeting

Elizabeth A. Schlenk, PhD, RN, FAAN, & Afton L. Hassett, PsyD  |  December 19, 2017

The ACR Board of Directors approved the ARHP Master Designation at its August 2017 meeting. The first two ARHP Master Designation awardees will be honored at the ACR/ARHP Annual Meeting in Chicago on Oct. 20, 2018. Recognition as a Master of the ARHP is one of the highest honors that the ARHP bestows to members….

Does MRI Differentiate Osteoarthritis and Meniscal Tear in Knee Pain?

Kelly April Tyrrell  |  December 19, 2017

When a young patient arrives at a clinic complaining of knee pain with clicking or popping, a meniscal tear is often the culprit. “In young [people], there’s a pretty classic presentation of meniscal tear, with clicking and other mechanical symptoms, because the tear rubs up against different tissues,” says Jeffrey Katz, MD, MSc, a rheumatologist…

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee  |  December 19, 2017

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 71
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences